Lexicon Pharmaceuticals (LXRX) Assets Average (2011 - 2026)

Lexicon Pharmaceuticals (LXRX) has 16 years of Assets Average data on file, last reported at $226.9 million in Q1 2026.

• On a quarterly basis, Assets Average fell 23.87% year-over-year to $226.9 million in Q1 2026; TTM through Mar 2026 was $226.9 million, a 23.87% decrease from a year earlier, with the FY2025 full-year figure at $241.7 million, down 8.42% from the prior year.
• Assets Average for Q1 2026 stood at $226.9 million, up from $195.5 million in the prior quarter.
• Over the last five years, Assets Average for LXRX reached as high as $395.3 million in Q2 2024 and fell as low as $124.3 million in Q2 2022.
• Historically, Assets Average has averaged $243.9 million across 5 years, with a median of $239.7 million in 2023.
• Across the five-year window, Assets Average soared 95.13% in 2023 and sank 37.87% in 2025, its largest moves.
• Year by year, Assets Average stood at $193.0 million in 2022, then surged by 31.07% to $253.0 million in 2023, then climbed by 22.46% to $309.8 million in 2024, then tumbled by 36.9% to $195.5 million in 2025, then climbed by 16.09% to $226.9 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $226.9 million in Q1 2026, $195.5 million in Q4 2025, and $215.8 million in Q3 2025.